Pharma sector in focus as major developments unfold across four key stocks. Sun Pharmaceutical announced its largest overseas acquisition, agreeing to buy US-based Organon for $14 per share in an all-cash deal valued at $11.75 billion, marking a significant milestone for Indian drugmakers. Zydus Lifesciences received regulatory approval to conduct Phase III clinical trials for Zintrodiazine in malaria treatment, advancing its pipeline in infectious diseases. Alembic Pharmaceuticals secured final FDA approval for Fingolimod Capsules, a multiple sclerosis treatment with an estimated market size of $145 million annually. Rubicon Research completed an unannounced FDA inspection at its Canadian facility without any compliance issues noted.
